Evidence map›Paper›PMID 26513502›Full record

ArticleInvestigative ophthalmology & visual science2015

Pathological Effects of Mutant C1QTNF5 (S163R) Expression in Murine Retinal Pigment Epithelium.

Astra Dinculescu, Seok-Hong Min, Frank M Dyka, Wen-Tao Deng, Rachel M Stupay, Vince Chiodo, W Clay Smith, William W Hauswirth

Open access · bronzeAbstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Loss of CTRP5 improves insulin action and hepatic steatosis.American journal of physiology. Endocrinology and metabolism · 2016
    Article
  13. Targeting Lipid Metabolism for the Treatment of Age-Related Macular Degeneration: Insights from Preclinical Mouse Models.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Astra Dinculescu
Seok-Hong Min
Frank M Dyka
Wen-Tao Deng
Rachel M Stupay
Vince Chiodo
W Clay Smith
William W Hauswirth
University of Florida · US

Funding

RESEARCH TRAINING IN VISION SCIENCET32EY007132 · NEI · UNIVERSITY OF FLORIDA · PI W CLAY SMITH · 1991 to 2026
$3.8M
Vision Research CoreP30EY021721 · NEI · UNIVERSITY OF FLORIDA · PI HAUSWIRTH, WILLIAM W · 2011 to 2015
$2.8M
Nanoparticle & AAV Approaches to Rapid Onset, Stable Retinal Gene TherapyR21EY018331 · NEI · UNIVERSITY OF FLORIDA · PI PANG, JIJING · 2007 to 2008
$398k
NEI NIH HHS EY018331NEI NIH HHS EY021721NEI NIH HHS P30 EY021721NEI NIH HHS R21 EY018331NEI NIH HHS T32 EY007132
6 · The paper itself

Abstract

purposeThe mutation S163R in complement C1q tumor necrosis factor-related protein-5 (C1QTNF5) causes an autosomal dominant disorder known as late-onset retinal degeneration (L-ORD). In this study, our goal is to evaluate the consequences of mutant S163R C1QTNF5 expression in mouse RPE following its delivery using an adeno-associated viral (AAV) vector.

methodsWe generated AAV vectors containing either human wild-type C1QTNF5 or mutant S163R C1QTNF5 driven by an RPE-specific BEST1 promoter, and delivered them subretinally into one eye of adult C57BL/6 mice. Transgene expression was detected by immunohistochemistry. Retinal function was assessed by full-field ERG. Pathological changes were further examined by digital fundus imaging and spectral-domain optical coherence tomography (SD-OCT).

resultsWe show that the AAV-expressed mutant S163R leads to pathological effects similar to some of those found in patients with advanced L-ORD, including RPE thinning, RPE cell loss, and retinal degeneration. In addition, we provide in vivo evidence that mutant S163R C1QTNF5 can form large, transparent, spherical intracellular aggregates throughout the RPE, which are detectable by light microscopy. In contrast to AAV-expressed wild-type C1QTNF5, which is secreted apically from the RPE toward the photoreceptor cells and the outer limiting membrane, the S163R mutant is primarily routed toward the basal side of RPE, where it forms thick, extracellular deposits over time.

conclusionsAdeno-associated viral-targeted expression of mutant S163R in the RPE represents a useful approach for quickly generating animal models that mimic pathological features of L-ORD and offers the potential to understand disease mechanisms and develop therapeutic strategies.

Indexed as

AnimalsBestrophinsBlotting, WesternEye ProteinsFundus OculiGene ExpressionIon ChannelsMembrane ProteinsMiceMice, Inbred C57BLMice, TransgenicMicroscopy, Electron, TransmissionMutation, MissenseRetinal DegenerationRetinal Pigment EpitheliumTomography, Optical CoherenceBest1 protein, mouseBestrophinsCTRP5 protein, mouseEye ProteinsIon ChannelsMembrane Proteins

Identifiers

PMID26513502
PMCPMC4627469
OpenAlexW2408341504

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.